• 1
    Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007;11:1160.
  • 2
    Van de Werf F, Bax J, Betriu A, et al; ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008;29:29092945.
  • 3
    Waters DD, Ku I. Early statin therapy in acute coronary syndromes: the successful cycle of evidence, guidelines, and implementation. J Am Coll Cardiol. 2009;54:14341437.
  • 4
    Karter AJ, Parker MM, Moffet HH, et al. New prescription medication gaps: a comprehensive measure of adherence to new prescriptions. Health Serv Res. 2009;44(5 part 1):16401661.
  • 5
    Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288: 455461.
  • 6
    Helin-Salmivaara A, Lavikainen P, Korhonen MJ, et al. Long-term persistence with statin therapy: a nationwide register study in Finland. Clin Ther. 2008;30(part 2):22282240.
  • 7
    Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998;279: 14581462.
  • 8
    Blackburn DF, Dobson RT, Blackburn JL, et al. Adherence to statins, β-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can J Cardiol. 2005;21:485488.
  • 9
    West of Scotland Study Group. Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. Eur Heart J. 1997;18:17181724.
  • 10
    McGinnis B, Olson KL, Magid D, et al. Factors related to adherence to statin therapy. Ann Pharmacother. 2007;41:18051811.
  • 11
    Shalev V, Chodick G, Silber H, et al. Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med. 2009;169:260268.
  • 12
    Jackevicius CA, Anderson GM, Leiter L, et al. Use of the statins in patients after acute myocardial infarction: does evidence change practice? Arch Intern Med 2001;161:183188.
  • 13
    Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288:462467.
  • 14
    Vaara S, Nieminen MS, Lokki M-L, et al. Cohort Profile: the Corogene study. Int J Epidemiol 2011; doi:10.1093/ije/dyr090.
  • 15
    Bassand JP, Hamm CW, Ardissino D, et al; Task Force for Diagnosis and Treatment of Non–ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology. Guidelines for the diagnosis and treatment of non–ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28:15981660.
  • 16
    Helin-Salmivaara A, Lavikainen PT, Korhonen MJ, et al. Pattern of statin use among 10 cohorts of new users from 1995 to 2004: a register-based nationwide study. Am J Manag Care. 2010; 16:116122.
  • 17
    Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:13831389.
  • 18
    Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [published corrections appear in Lancet. 2005;366:1358 and Lancet. 2008;371:2084]. Lancet. 2005;366:12671278.
  • 19
    The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339:13491357.
  • 20
    Cooke CA, Kirkland SA, Sketris IS, et al. The impact of statins on health services utilization and mortality in older adults discharged from hospital with ischemic heart disease: a cohort study. BMC Health Serv Res. 2009;9:198.
  • 21
    Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333:15.
  • 22
    Hippisley-Cox J, Coupland C. Effect of statins on the mortality of patients with ischaemic heart disease: population based cohort study with nested case-control analysis. Heart. 2006;92:752758.
  • 23
    Ab E, Denig P, van Vliet T, et al. Reasons of general practitioners for not prescribing lipid-lowering medication to patients with diabetes: a qualitative study. BMC Fam Pract. 2009;10:24.
  • 24
    Ohlsson H, Merlo J. Is physician adherence to prescription guidelines a general trait of health care practices or dependent on drug type?—a multilevel logistic regression analysis in South Sweden. Pharmacoepidemiol Drug Saf. 2009;18:682690.
  • 25
    Cohen SM, Kataoka-Yahiro M. Provider adherence to clinical guidelines related to lipid-lowering medications. Mil Med. 2010;175:122126.
  • 26
    Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation. 2008;117:10281036.
  • 27
    Ellis JJ, Erickson SR, Stevenson JG, et al. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med. 2004;19:638645.
  • 28
    Sacks FM, Pfeffer MA, Moye LA, et al; Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:10011009.
  • 29
    McDermott MM, Schmitt B, Wallner E. Impact of medication nonadherence on coronary heart disease outcomes: a critical review. Arch Intern Med. 1997;157:19211929.
  • 30
    Dragomir A, Côté R, White M, et al. Relationship between adherence level to statins, clinical issues and health-care costs in real-life clinical setting. Value Health. 2010;13:8794.